Die and let live: harnessing BikDD to combat breast cancer stem cells

Area of Science:

• Oncology
• Cancer Biology
• Gene Therapy

Background:

• Cancer stem cells (CSCs) exhibit intrinsic resistance to conventional therapies.
• Inefficient activation of apoptotic machinery is a key mechanism of CSC resistance.
• Targeting CSCs is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy of an engineered pro-apoptotic protein, BikDD, against cancer stem cells.
• To investigate the potential of a cancer cell-specific gene-therapy approach for delivering BikDD.
• To assess the synergistic effects of BikDD with existing chemotherapies.

Main Methods:

• Engineering a constitutively active pro-apoptotic protein (BikDD) that inhibits Bcl-2 family members.
• Developing an innovative cancer cell-specific gene-therapy delivery system for BikDD.
• Testing BikDD in preclinical breast cancer models, including those with CSC populations.

Main Results:

• BikDD demonstrated potent anti-CSC activity in preclinical breast cancer models.
• The gene-therapy delivery of BikDD was effective in targeting cancer cells.
• BikDD synergized with lapatinib and paclitaxel, enhancing their therapeutic effects.

Conclusions:

• Engineered BikDD delivered via cancer cell-specific gene therapy is a promising strategy against CSCs.
• This novel approach overcomes intrinsic resistance mechanisms in cancer stem cells.
• Further clinical translation of BikDD-based gene therapy for breast cancer is warranted.